LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve RET-mutant medullary thyroid cancer

Selpercatinib is a first-in-class, highly selective and potent, central nervous system-active RET kinase inhibitor. In the phase I/II trial, selpercatinib demonstrated clinically meaningful antitumor activity with manageable toxicity in heavily pre-treated and treatment-naive patients with RET-mutan...

Descripción completa

Detalles Bibliográficos
Autores principales: Wirth, Lori J, Brose, Marcia S, Elisei, Rossella, Capdevila, Jaume, Hoff, Ana O, Hu, Mimi I, Tahara, Makoto, Robinson, Bruce, Gao, Ming, Xia, Meng, Maeda, Patricia, Sherman, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Clinical Trial Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652291/
https://www.ncbi.nlm.nih.gov/pubmed/35969032
http://dx.doi.org/10.2217/fon-2022-0657

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10652291/
https://www.ncbi.nlm.nih.gov/pubmed/35969032
http://dx.doi.org/10.2217/fon-2022-0657

Ejemplares similares